Short answer
Exelixis Inc (EXEL) filed its Q3 2019 10-Q quarterly report on Oct 30, 2019 for the quarter ended Sep 27, 2019.
Exelixis Inc Q3 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $271.7M vs $225.4M YoY; net product revenue $191.8M vs $162.9M
- Net income $97.5M vs $126.6M; effective tax rate 20.5% vs 1.8% YoY
- CABOMETYX revenue $187.4M vs $158.3M; COMETRIQ $4.4M vs $4.7M
- Cash and investments $1.2B vs $851.6M at December 31, 2018; nine-month operating cash flow $368.9M
- R&D expense $97.3M vs $44.7M; management expects continued increases amid expanded cabozantinib development and pipeline spending
Risk Factors
- Newly triggered generic-competition risk: MSN’s October 2019 ANDA challenged CABOMETYX patents, prompting Exelixis’s October 29 infringement complaint
- Most materially updated legal risk: CABOMETYX patent litigation seeks exclusivity through October 8, 2030, but MSN could launch after composition patent expiry on August 16, 2026
- Regulatory compliance risk: March 2019 Senate Finance Committee inquiry increased scrutiny of pharmaceutical donations to patient-assistance foundations
- Near-term market risk: Intensifying ICI-based oncology competition could impair CABOMETYX’s relative efficacy and market acceptance
- Financial risk: Growth investments may require additional capital despite $1,248.4 million cash and investments at September 30, 2019
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Exelixis Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.